Riviera Tool Co (RIVT) 0.2250 $RIVT
Confusion Causes
Riviera Tool Co (RIVT) 0.2250 $RIVT
Confusion Causes 12,000% Run Up In Riviera Tools Company
Auspex Research - Seeking Alpha - Fri May 08, 10:43AM CDT
News of Tesla's acquisition of a Michigan-based auto supplier caused a great deal of confusion today. When Tesla (NASDAQ: TSLA ) announced that they had purchased Riviera Tools for an undisclosed amount, shares of Pink Sheet delinquent filer Riviera...
TSLA: 250.24 (+1.76)
Mistaken identity suspected in Tesla-fueled rally in Riviera Tool
Seeking Alpha - at Seeking Alpha - Fri May 08, 8:23AM CDT
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...
Continue Reading
Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...
Continue Reading
What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...
Continue Reading
A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...
Continue Reading
Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....
Continue Reading
Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...
Continue Reading
Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...
Continue Reading
BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...
Continue Reading
Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...
Continue Reading
Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...
Continue Reading
Top 5 Most Recently Viewed Articles
Healthcare Realty Trust Quarterly Results Overview Healthcare Realty Trust Incorporated (NYSE: HR) has reported its fourth quarter results for the year 2024, highlighting significant developments in its operations and financial performance. The company recorded a net (loss) income attributable to common stockholders of $(106.8) million, or $(0.31) per diluted share,...
Continue Reading
Brown Gibbons Lang & Company (BGL) has just sealed the deal on a significant sale—Western Botanicals, a prominent player in the Vitamins, Minerals, and Supplements (VMS) contract development and manufacturing space, is headed to The Riverside Company. Now this isn’t just another corporate shuffle; it's BGL’s third foray into the CDMO subsector and marks their fourth...
Continue Reading
High Arctic Energy Services Reports Strong Second Quarter Results High Arctic Energy Services Inc. (TSX: HWO), a noted energy services provider, has recently shared its financial results for the second quarter of 2025, highlighting a continued commitment to operational excellence amid challenging market conditions. 2025 Second Quarter Performance Overview The company...
Continue Reading
DXC Technology Class Action Notice for Shareholders The Gross Law Firm has released an important notice for shareholders of DXC Technology Company (NYSE: DXC). This notice is aimed at individuals who acquired shares during the specified class period. Shareholders are encouraged to reach out to the firm if they are interested in being considered for the role of lead...
Continue Reading
Manulife: Debuting $750M in Subordinated Notes When it comes to Manulife's latest move, it's all about the numbers. They've priced a U.S. public offering of a meaty $750 million in subordinated notes at an enticing 6.146% interest rate. That's no pocket change, folks, and it highlights a strategy or a gamble, depending on your view. But here's the kicker: these notes may...
Continue Reading